Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.

Transplantation - 15 Sept 2009

Massoumi Hatef, Elsiesy Hussein, Khaitova Viktoriya, Peterson Brent, Norkus Edward, Grewal Priya, Liu Lawrence, Chang Charissa, Bach Nancy, Schiano Thomas D

Abstract excerpt

BACKGROUND: To lessen the severity of recurrent hepatitis C virus (HCV) postliver transplantation (post-LT) by treating HCV patients with cirrhosis, we assessed the safety and efficacy of an escalating dose pegylated interferon (PEG-IFN)/ribavirin protocol in pre-LT patients. METHODS: Ninety patients were treated with 90 microg PEG-IFN alpha-2a and 400 mg ribavirin and advanced to 180 microg and 800 to 1200 mg,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 19741473
DOI: 10.1097/TP.0b013e3181b2e0d1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.PMID 19741473Read ↗

Hepatitis C virus in the transplant setting.Semantic proximity Read ↗

Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.Semantic proximity Read ↗

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Semantic proximity Read ↗

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.Semantic proximity Read ↗

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.Semantic proximity Read ↗

Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.Semantic proximity Read ↗

Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.Semantic proximity Read ↗

Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.Semantic proximity Read ↗

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.Semantic proximity Read ↗

Hepatitis C treatment in patients on the liver transplant waiting list.Semantic proximity Read ↗

Daily interferon therapy for hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.